Company Overview

Natera Inc. is a global diagnostics company providing advanced molecular testing services. Headquartered in Austin, Texas, and founded in 2003, Natera specializes in cell-free DNA (cfDNA) testing across women's health, oncology, and organ health. Their cutting-edge cfDNA technology platform integrates novel molecular biology techniques with sophisticated bioinformatics software and AI, enabling detection at the single-molecule level.

This powerful platform has led to the development of industry-leading products such as Panorama™, the most accurate non-invasive prenatal test (NIPT) available; Signatera™, a tumor-specific assay for personalized cancer monitoring and recurrence surveillance; and Prospera™, a best-in-class test for assessing active rejection in kidney, heart, and lung transplant patients. The company also offers Altera, a tissue-based genomic profiling test, and Renasight, a kidney gene panel test, alongside its Constellation cloud-based software product.

Business Segments and Products

Natera's growth is driven by its core product families, each addressing critical needs in healthcare:

Oncology Solutions

The Signatera™ cell-free DNA test is central to the company's oncology offerings, providing minimal residual disease (MRD) detection and tumor-specific molecular tracking for personalized cancer monitoring and management. This test represents a significant advancement in early detection of cancer recurrence.

Women's Health Testing

Natera's Panorama™ platform delivers comprehensive non-invasive prenatal testing (NIPT) for a wide range of chromosomal abnormalities and genetic conditions. Recently, Natera launched Fetal Focus, a groundbreaking NIPT for inherited conditions, addressing a key gap by screening for five commonly tested genes even when the biological father is unavailable.

Organ Health

The Prospera™ test offers advanced monitoring for organ transplant recipients, applicable to kidney, heart, and lung transplantation. Data from studies like DEFINE presented at ISHLT has shown Prospera's superior ability to predict graft dysfunction post-transplant, highlighting its clinical advantage in monitoring transplant patient health.

Financial Performance

Q2 2025 Financial Highlights (ended June 30, 2025)

- Total Revenue: $546.6 million, a 32.2% increase from $413.4 million in Q2 2024.

- Product Revenue Growth: Increased by 32.3% year-over-year.

- Gross Margin: Improved to 63.4% in Q2 2025, up from 58.8% in Q2 2024.

- Test Volume: Processed approximately 853,100 tests in Q2 2025 (839,300 accessioned), a 12.2% increase from 760,300 tests (744,000 accessioned) in Q2 2024.

Key Growth Metrics

- Oncology Growth: Performed approximately 188,800 oncology tests in Q2 2025, a 50.6% increase from 125,400 in Q2 2024. This includes record sequential growth of ~20,000 Signatera clinical units from Q1 2025.

- Cash Position: Generated $24.3 million in positive cash flow (GAAP). Maintained over $1 billion in liquidity ($1,016.0 million in cash, equivalents, investments, and restricted cash) with modest debt of $80.3 million as of June 30, 2025.

2025 Guidance Update

Natera raised its 2025 annual revenue outlook by $80 million at the midpoint, projecting revenues between $2.02 billion – $2.10 billion, up from the previous $1.94 billion – $2.02 billion range. Operating expenses outlook remains unchanged, reflecting confidence in core product line adoption.

Market Position and Validation

Natera (NASDAQ: NTRA) is a recognized leader in cell-free DNA testing and precision medicine. The company's technological prowess and clinical impact are underscored by more than 300 peer-reviewed publications featuring its technology. These studies, appearing in prestigious journals such as Nature and Nature Medicine, demonstrate Natera's significant contribution to scientific advancements and its leadership in the field. The company's market capitalization stands at approximately $23.3 billion.

Innovation and Technology

Natera has launched its proprietary AI foundation model platform, designed to accelerate innovation in diagnostic and therapeutic advancements within precision medicine. This platform is built upon one of the largest multimodal oncology datasets globally, comprising over 250,000 tumor exomes and more than 1 million plasma timepoints.

Operations and Infrastructure

- Address: 13011 McCallen Pass · Building A Suite 100 · Austin, TX 78753 · United States

- Contact: 650 980 9190

- Website: https://www.natera.com

- Sector: Healthcare

- Industry: Diagnostics & Research

- Full-Time Employees: 4,424

Natera operates ISO 13485-certified and CAP-accredited laboratories, CLIA-certified in Austin, Texas, and San Carlos, California. The company serves healthcare providers through a multi-channel approach, including direct sales and a network of laboratory and distribution partners. It caters to independent laboratories, national and regional reference laboratories, medical centers, physician practices, research laboratories, and pharmaceutical companies.

Natera continues to solidify its leadership in genetic testing and precision medicine, showing consistent growth across its three core business segments and driving innovation to improve patient outcomes worldwide.